| 摘要 |
FIELD: medicine. ^ SUBSTANCE: invention refers to versions of Neisseria, particularly meningococcal vesicular agents or vaccines produced of vesicles of outer membrane. There are also disclosed preferential methods and vaccine products based on application of new L2 immunotype LOS (lipooligosaccharides) and/or L3 immunotype LOS, including subunit vaccines or meningococcal vaccines produced of vesicles of outer membrane, as well as an immunogenic composition used for prevention or treatment of Neisseria-caused disease. There are described combined genes of negative regulation, such as PorA and OpA, PorA and OpC, OpA and OpC, PorA and OpA and OpC. It is alternatively or additionally shown that IgtB- represents an ideal mutation for effective and safe use of L3 and/or L2 LOS in Neisseria vaccine compositions. Besides, there are vesicular vaccines produced of IgtB- and meningococcal mutants, defective in capsular-like polysaccharide, as well as preferential methods for preparing the vesicular agents, where LOS shall be preserved as a constitutive antigen. ^ EFFECT: agents prepared under the present invention are safer and/or more effective for human application. ^ 29 cl, 12 dwg, 1 tbl, 11 ex |
